TY - JOUR
T1 - Proximal-type epithelioid sarcoma in pubic region expressing L-type amino acid transporter 1
T2 - A case report
AU - Yahiro, Shunsuke
AU - Fujimoto, Takuya
AU - Fujita, Ikuo
AU - Takai, Toshihiro
AU - Sakuma, Toshiko
AU - Sudo, Tamotsu
AU - Morishita, Masayuki
AU - Takigami, Shunsaku
AU - Kawamoto, Teruya
AU - Hara, Hitomi
AU - Akisue, Toshihiro
AU - Kuroda, Ryosuke
AU - Hirose, Takanori
N1 - Publisher Copyright:
© The Author(s) 2022.
PY - 2022/1
Y1 - 2022/1
N2 - Proximal-type epithelioid sarcoma is an aggressive malignant soft-tissue neoplasm, a “proximal” variant of epithelioid sarcoma, resistant to multimodal therapy and involved in early tumor-related death. Pertinent treatments are, therefore, continually being explored. A 24-year-old woman with nonmetastatic proximal-type epithelioid sarcoma, originating subcutaneously on the right side of the vulva, underwent surgical resection; the lesion recurred, however, leading to death 3 months after the second surgery. Here described is a case of proximal-type epithelioid sarcoma expressing L-type amino acid transporter 1 (LAT1) that transports essential amino acids and p-borono-L-phenylalanine (BPA)—the chemical compound used in boron neutron capture therapy (BNCT)—and is highly expressed in many malignant tumors. Recently, LAT1 has drawn attention, and relevant treatments have been studied—LAT1 inhibitor and BNCT. LAT1 expression in proximal-type epithelioid sarcoma may lead to cogent treatments for the disease.
AB - Proximal-type epithelioid sarcoma is an aggressive malignant soft-tissue neoplasm, a “proximal” variant of epithelioid sarcoma, resistant to multimodal therapy and involved in early tumor-related death. Pertinent treatments are, therefore, continually being explored. A 24-year-old woman with nonmetastatic proximal-type epithelioid sarcoma, originating subcutaneously on the right side of the vulva, underwent surgical resection; the lesion recurred, however, leading to death 3 months after the second surgery. Here described is a case of proximal-type epithelioid sarcoma expressing L-type amino acid transporter 1 (LAT1) that transports essential amino acids and p-borono-L-phenylalanine (BPA)—the chemical compound used in boron neutron capture therapy (BNCT)—and is highly expressed in many malignant tumors. Recently, LAT1 has drawn attention, and relevant treatments have been studied—LAT1 inhibitor and BNCT. LAT1 expression in proximal-type epithelioid sarcoma may lead to cogent treatments for the disease.
KW - CD98
KW - Epithelioid sarcoma
KW - L-type amino acid transporter 1 (LAT1)
KW - LAT1 inhibitor
KW - boron neutron capture therapy (BNCT)
KW - p-borono-L-phenylalanine (BPA)
KW - proximal-type
UR - https://www.scopus.com/pages/publications/85122450385
UR - https://www.scopus.com/pages/publications/85122450385#tab=citedBy
U2 - 10.1177/2050313X211067917
DO - 10.1177/2050313X211067917
M3 - Article
AN - SCOPUS:85122450385
SN - 2050-313X
VL - 10
JO - SAGE Open Medical Case Reports
JF - SAGE Open Medical Case Reports
ER -